Treatment of bleeding in dialysis patients

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Bleeding is a common and potentially serious complication of acute and chronic renal failure. The pathogenesis of bleeding in uremia is multifactorial; however, the major role is played by abnormalities in platelet-platelet and platelet-vessel wall interaction. Platelet dysfunction is partially due to uremic toxins present in circulating blood. Despite decreased platelet function, abnormalities of blood coagulation and fibrinolysis predispose the uremic patients to a hypercoagulable state carrying the risk of cardiovascular and thrombotic complications. Dialysis improves platelet abnormalities and reduces, but does not eliminate, the risk of hemorrhage. Hemodialysis can even contribute to the bleeding through the continuous platelet activation induced by the interaction between blood and artificial surfaces and the use of anticoagulants. Correction of anemia improves hemostasis in uremic patients. Therapeutic management of bleeding in patients with uremia is discussed.

Original languageEnglish
Pages (from-to)279-286
Number of pages8
JournalSeminars in Dialysis
Volume22
Issue number3
DOIs
Publication statusPublished - May 2009

Fingerprint

Dialysis
Blood Platelets
Hemorrhage
Uremia
Therapeutics
Blood Substitutes
Platelet Activation
Blood Coagulation
Fibrinolysis
Hemostasis
Acute Kidney Injury
Anticoagulants
Chronic Kidney Failure
Renal Dialysis
Anemia

ASJC Scopus subject areas

  • Nephrology

Cite this

Treatment of bleeding in dialysis patients. / Galbusera, Miriam; Remuzzi, Giuseppe; Boccardo, Paola.

In: Seminars in Dialysis, Vol. 22, No. 3, 05.2009, p. 279-286.

Research output: Contribution to journalArticle

@article{0b8aa6f3ea8842af861509c4e3792182,
title = "Treatment of bleeding in dialysis patients",
abstract = "Bleeding is a common and potentially serious complication of acute and chronic renal failure. The pathogenesis of bleeding in uremia is multifactorial; however, the major role is played by abnormalities in platelet-platelet and platelet-vessel wall interaction. Platelet dysfunction is partially due to uremic toxins present in circulating blood. Despite decreased platelet function, abnormalities of blood coagulation and fibrinolysis predispose the uremic patients to a hypercoagulable state carrying the risk of cardiovascular and thrombotic complications. Dialysis improves platelet abnormalities and reduces, but does not eliminate, the risk of hemorrhage. Hemodialysis can even contribute to the bleeding through the continuous platelet activation induced by the interaction between blood and artificial surfaces and the use of anticoagulants. Correction of anemia improves hemostasis in uremic patients. Therapeutic management of bleeding in patients with uremia is discussed.",
author = "Miriam Galbusera and Giuseppe Remuzzi and Paola Boccardo",
year = "2009",
month = "5",
doi = "10.1111/j.1525-139X.2008.00556.x",
language = "English",
volume = "22",
pages = "279--286",
journal = "Seminars in Dialysis",
issn = "0894-0959",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Treatment of bleeding in dialysis patients

AU - Galbusera, Miriam

AU - Remuzzi, Giuseppe

AU - Boccardo, Paola

PY - 2009/5

Y1 - 2009/5

N2 - Bleeding is a common and potentially serious complication of acute and chronic renal failure. The pathogenesis of bleeding in uremia is multifactorial; however, the major role is played by abnormalities in platelet-platelet and platelet-vessel wall interaction. Platelet dysfunction is partially due to uremic toxins present in circulating blood. Despite decreased platelet function, abnormalities of blood coagulation and fibrinolysis predispose the uremic patients to a hypercoagulable state carrying the risk of cardiovascular and thrombotic complications. Dialysis improves platelet abnormalities and reduces, but does not eliminate, the risk of hemorrhage. Hemodialysis can even contribute to the bleeding through the continuous platelet activation induced by the interaction between blood and artificial surfaces and the use of anticoagulants. Correction of anemia improves hemostasis in uremic patients. Therapeutic management of bleeding in patients with uremia is discussed.

AB - Bleeding is a common and potentially serious complication of acute and chronic renal failure. The pathogenesis of bleeding in uremia is multifactorial; however, the major role is played by abnormalities in platelet-platelet and platelet-vessel wall interaction. Platelet dysfunction is partially due to uremic toxins present in circulating blood. Despite decreased platelet function, abnormalities of blood coagulation and fibrinolysis predispose the uremic patients to a hypercoagulable state carrying the risk of cardiovascular and thrombotic complications. Dialysis improves platelet abnormalities and reduces, but does not eliminate, the risk of hemorrhage. Hemodialysis can even contribute to the bleeding through the continuous platelet activation induced by the interaction between blood and artificial surfaces and the use of anticoagulants. Correction of anemia improves hemostasis in uremic patients. Therapeutic management of bleeding in patients with uremia is discussed.

UR - http://www.scopus.com/inward/record.url?scp=67649628258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649628258&partnerID=8YFLogxK

U2 - 10.1111/j.1525-139X.2008.00556.x

DO - 10.1111/j.1525-139X.2008.00556.x

M3 - Article

C2 - 19573008

AN - SCOPUS:67649628258

VL - 22

SP - 279

EP - 286

JO - Seminars in Dialysis

JF - Seminars in Dialysis

SN - 0894-0959

IS - 3

ER -